About Intus Bio
Intus Bio is a company based in Farmington (United States) founded in 2014. Intus Bio has raised $4.14 million across 5 funding rounds from investors including HHS. Intus Bio has completed 1 acquisition, including Pattern Genomics. Intus Bio offers products and services including Titan-1™ Platform and GutID. Intus Bio operates in a competitive market with competitors including Inflammatix, Visby Medical, MeMed, Pendulum and GenMark Diagnostics, among others.
- Headquarter Farmington, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Intus Biosciences, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.14 M (USD)
in 5 rounds
-
Latest Funding Round
$1.09 M (USD), Seed
May 15, 2025
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Intus Bio
Intus Bio offers a comprehensive portfolio of products and services, including Titan-1™ Platform and GutID.
AI-powered system for high-resolution microbiome data and strain tracking.
Home-based test for personal gut microbiome analysis and insights.
People of Intus Bio
Unlock access to complete
R Team
1 people
Leadership Team
1 people
Co Team
1 people
Software Development Team
1 people
Microbiome Team
1 people
Unlock access to complete
Funding Insights of Intus Bio
Intus Bio has successfully raised a total of $4.14M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $1.09 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intus Bio
Intus Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Intus Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intus Bio
Intus Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pattern Genomics.
Investment portfolio details for Intus Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Large-scale bioinformatics sequence analysis is applied for molecular assay design.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Intus Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Intus Bio
Detailed financials for Intus Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intus Bio Comparisons
Peer comparison for Intus Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intus Bio
Intus Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Visby Medical, MeMed, Pendulum and GenMark Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Pendulum is focused on developing advanced probiotic solutions.
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Point-of-care molecular platforms for infectious disease detection are developed.
|
Detailed competitors of Intus Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intus Bio
Complete news archive for Intus Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intus Bio
Intus Bio was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Intus Bio is headquartered in Farmington, United States.
Ken Beers is the current CEO of Intus Bio.
Intus Bio is a funded company, having raised a total of $4.14M across 5 funding rounds to date.
Intus Bio was founded in 2014 in Farmington, United States, within the biotechnology sector. Sequencing technology is provided for microbiome testing, pathogen identification, and tracking. A platform named Titan-1 is utilized, employing a patented 16S-ITS-23S amplicon to distinguish bacterial strains without requiring full genome sequencing. Operations focus on enabling efficient microbial analysis for research and diagnostic applications.
Intus Bio's top competitors include Visby Medical, Tessera Therapeutics and Inflammatix.
Intus Bio offers Titan-1™ Platform and GutID.
Intus Bio has made 1 acquisition, including Pattern Genomics.
Intus Bio has 1 investor. Key investors include HHS.